RESUMO
There is growing clinical evidence in support of a diet for irritable bowel syndrome (IBS) that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). This low FODMAP diet is gaining acceptance globally among clinicians and IBS sufferers alike. However, there is disparity concerning the success rates of the FODMAP diet between patients, which can be attributed to differences in the recommended diet itself and to adherence issues. To address the differences in the diet, a generally accepted science-based definition of the analytical criteria for low FODMAP products suitable for a low FODMAP diet should be developed. To address the adherence challenge, regulators should permit manufacturers of low FODMAP products to communicate the benefits of a low FODMAP diet on product labels and promotional material which will facilitate people with IBS' selection and use low FODMAP foods.
